Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis-Reference-Cited by-同舟云学术

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis

Published:2016-11-02 Issue:11 Volume:11 Page:e0162752
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bachelet Delphine,Hässler Signe^ORCID,Mbogning Cyprien,Link Jenny,Ryner Malin,Ramanujam Ryan,Auer Michael,Hyldgaard Jensen Poul Erik,Koch-Henriksen Nils,Warnke Clemens,Ingenhoven Kathleen,Buck Dorothea,Grummel Verena,Lawton Andy,Donnellan Naoimh,Hincelin-Mery Agnès,Sikkema Dan,Pallardy Marc,Kieseier Bernd,Hemmer Bernard,Hartung Hans Peter,Soelberg Sorensen Per,Deisenhammer Florian,Dönnes Pierre,Davidson Julie,Fogdell-Hahn Anna,Broët Philippe,

Funder

Innovative Medicines Initiative

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference52 articles.

1. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes;F Deisenhammer;CNS Drugs,2009

2. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group;A Bertolotto;Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol,2014

3. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis;PS Sørensen;Eur J Neurol,2005

4. Interferon-Beta: Neutralizing Antibodies, Binding Antibodies, Pharmacokinetics and Pharmacodynamics, and Clinical Outcomes;F Deisenhammer;J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res,2014

5. Using measurements of neutralizing antibodies: the challenge of IFN-β therapy;D Hesse;Eur J Neurol,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

2. Addressing Smoking in Persons With Multiple Sclerosis: State of the Science and Need for a Targeted Intervention;Nicotine and Tobacco Research;2023-08-25

3. Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis;Journal of Neuroimmunology;2022-09

4. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

5. Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?;Frontiers in Neurology;2022-04-15